Jaime Chu, MD

Dr. Jaime Chu is the Mount Sinai Endowed Professor of Pediatric Liver Research, the Associate Chief of the Division of Pediatric Hepatology, Medical Director of Pediatric Liver Transplantation, Director of the Pediatric Physician-Scientist Residency Program, and Associate Director of the MD/PhD (MSTP) Program at the Mount Sinai Kravis Children’s Hospital, Mount Sinai’s Recanati/Miller Transplantation Institute, and Icahn School of Medicine at Mount Sinai. She received her B.A. magna cum laude from Harvard University and her M.D. from New York University School of Medicine.  She completed her General Pediatrics residency training at Northwestern University/Children’s Memorial Hospital (now Lurie Children's Hospital of Chicago) at Northwestern University in Chicago, IL and her fellowship in Pediatric Gastroenterology, Hepatology, and Nutrition both at Children’s Memorial Hospital and at the Mount Sinai School of Medicine.

Dr. Chu is a physician-scientist in pediatric hepatology. She runs an NIH R01-funded basic research group that focuses on how sugar metabolism pathways work together to sustain rapid cell growth in liver development and disease. The lab focuses on the role of mannose metabolism pathways in liver fibrosis. The Chu Lab capitalizes on the strength of the zebrafish as a tool to investigate metabolic mechanisms of hepatic stellate cell activation and test potential therapies to dampen the fibrogenic response. Her research has been awarded the Gilead Sciences Research Scholars Liver Disease Award, AASLD Foundation Bridge Award and R01 funding from the NIH/NIDDK to examine the role of mannose metabolism in liver fibrosis. Dr. Chu's clinical research includes participation as site PI and co-Investigator in NIH-funded consortia including a U01 Pediatric Acute Liver Failure, and other Industry-sponsored pediatric drug trials for genetic cholestatic liver disease, biliary atresia, and viral hepatitis. She is MPI on two R38 awards (NHLBI and NIAID), which support training in research during residency. Dr. Chu has served on study sections for the NIDDK, and NCATS, and as a member of the AASLD Task Force on COVID-19. Dr. Chu's long-term goal is to utilize collaborative science and integrate basic and clinical research towards improving our understanding of the mechanisms underlying pediatric liver disease and to apply this knowledge towards the development of much needed therapeutic options for children with liver disease. For more information, please see the Chu Lab website: http://labs.icahn.mssm.edu/chulab/